Moderate-to-severe Atopic Dermatitis Clinical Trial
Official title:
Neuropsychologic Assessments of Dupilumab-Treated Adolescents With Moderate-to-Severe Atopic Dermatitis
Primary Objective: Part A - To quantify deficits in cognitive functioning in adolescents with moderate-to-severe AD, using the Conners' Continuous Performance Test 3rd Edition (CPT-3) d' T-score - To determine the entry criterion (CPT-3 d' score) for Part B Primary Objective: Part B - To measure changes in cognitive functioning in adolescents with moderate-to-severe AD treated with dupilumab Secondary Objectives - To evaluate the relationship of cognitive and sensory functioning with severity of AD in adolescent AD patients - To evaluate the relationship between changes in AD severity and changes in cognitive and sensory functioning scores following treatment with dupilumab (Part B only).
Per protocol Study Stop Criteria, study has concluded with Part A. Part B was not initiated and no data were collected. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03054428 -
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Active, not recruiting |
NCT05899816 -
A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)
|
Phase 3 | |
| Recruiting |
NCT04893707 -
The Study of CM310 in Patients With Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT03989349 -
Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | |
| Completed |
NCT03985943 -
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT04921345 -
Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis
|
Phase 2 | |
| Completed |
NCT04893941 -
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
|
Phase 1/Phase 2 | |
| Completed |
NCT04444752 -
A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
|
Phase 2 | |
| Withdrawn |
NCT05056779 -
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
|
Phase 3 | |
| Active, not recruiting |
NCT05590585 -
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
|
Phase 4 | |
| Completed |
NCT04805411 -
Subcutaneously CM310/Placebo in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
|
Phase 2 | |
| Recruiting |
NCT05186922 -
The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03057860 -
TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
|
||
| Active, not recruiting |
NCT03989206 -
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis
|
Phase 3 | |
| Recruiting |
NCT05671432 -
The Study of CM326 in Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
| Not yet recruiting |
NCT06158490 -
A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis
|
Phase 2 | |
| Terminated |
NCT05984784 -
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)
|
Phase 1/Phase 2 | |
| Completed |
NCT05017480 -
A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China
|
Phase 2 |